<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311518</url>
  </required_header>
  <id_info>
    <org_study_id>RGN-MI-201</org_study_id>
    <nct_id>NCT01311518</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Study of the Safety and Efficacy of RGN-352 in Subjects With an Acute ST Elevation Myocardial Infarction (STEMI) After Occlusion of the Proximal Left Anterior Descending Coronary Artery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RegeneRx Biopharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RegeneRx Biopharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and tolerability of two active doses of&#xD;
      RGN-352 (thymosin beta 4, Tβ4, Injectable Solution) in patients with acute myocardial&#xD;
      infarction receiving percutaneous coronary intervention angioplasty with or without stent&#xD;
      placement. Approximately 75 subjects will be randomized to receive one of two RGN-352 doses&#xD;
      of 1200 mg, or 450 mg, or placebo, administered iv by iv push daily for the first 3&#xD;
      consecutive days and weekly for 4 more weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo controlled, parallel-group, dose finding study. Eligible&#xD;
      subjects will be randomized to receive one of two doses of RGN-352 or matching placebo with&#xD;
      an equal allocation ratio (i.e., 1:1:1). Approximately 75 subjects will be randomized to&#xD;
      study treatment to achieve at least 60 evaluable subjects with 20 to 25 subjects per group.&#xD;
      Subjects will be randomized to receive one of two RGN-352 doses of 1200 mg, or 450 mg, or&#xD;
      placebo, administered iv by iv push daily for the first 3 consecutive days and weekly for 4&#xD;
      consecutive weeks. Study subjects will undergo cardiac angiography to assess initial coronary&#xD;
      artery patency and Thrombolysis In Myocardial Infarction flow grade both pre- and&#xD;
      post-percutaneous coronary intervention (PCI) angioplasty. A total of 7 doses will be&#xD;
      administrated over the treatment period. The first dose of either RGN-352 or placebo will be&#xD;
      administered to randomized subjects following PCI angioplasty and specifically within 30&#xD;
      minutes after balloon deflation, with a further 2 doses. The remaining 4 doses will be given&#xD;
      weekly for 4 consecutive weeks. Follow-up is on Months 2, 4, and 6.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Trial never initiated&#xD;
  </why_stopped>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total MRI infarct zone derived from cardiac MRI scan</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI-derived myocardial salvage index, mass, Left Ventricle (LV) ejection fraction,systolic and end diastolic volumes</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: Thymosin Beta 4 injectable</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Placebo</intervention_name>
    <description>Injectable administration by slow intravenous bolus, 0.00% Thymosin Beta 4 daily for 3 days then weekly for 4 consecutive weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.00% Thymosin Beta 4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Injectable Thymosin beta 4</intervention_name>
    <description>Injectable administration of Thymosin Beta 4 by intravenous bolus at 1200 mg, or 450 mg daily for 3 days then weekly for 4 consecutive weeks</description>
    <arm_group_label>Drug: Thymosin Beta 4 injectable</arm_group_label>
    <other_name>Injectable Thymosin Beta 4</other_name>
    <other_name>Tβ4 Injectable Solution</other_name>
    <other_name>RGN-352</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects&#xD;
&#xD;
          2. Negative urine pregnancy test at Screening&#xD;
&#xD;
          3. An electrocardiogram&#xD;
&#xD;
          4. First acute anterior MI&#xD;
&#xD;
          5. Baseline angiography&#xD;
&#xD;
          6. Onset of chest pain symptoms to initial PCI angioplasty time is 2 to 6 hours&#xD;
&#xD;
          7. Written informed consent reviewed and signed by the subject or legally authorized&#xD;
             representatives&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intention to treat subject with thrombolytic therapy following assertion of&#xD;
             Thrombolysis In Myocardial Infarction(TIMI) flow 0 or 1 during qualifying angiogram&#xD;
&#xD;
          2. History of Myocardial infarctionI or congestive heart failure&#xD;
&#xD;
          3. Non-atherosclerotic etiology of acute myocardial infarction&#xD;
&#xD;
          4. Cardiogenic shock (systolic blood pressure &lt;90 despite adequate left ventricle filling&#xD;
             pressure or requiring catecholamines) or other hemodynamic instability at baseline&#xD;
&#xD;
          5. Further transcatheter or surgical revascularization, e.g., coronary artery bypass&#xD;
             graft planned per baseline angiogram&#xD;
&#xD;
          6. Lactating women&#xD;
&#xD;
          7. Past or present evidence of malignancy&#xD;
&#xD;
          8. Women who have had menarche but have not completed menopause, have not been surgically&#xD;
             sterilized (bilateral tubal ligation or hysterectomy), do not have a partner with&#xD;
             documented sterility (including vasectomy), or are not using adequate contraception&#xD;
             (combined hormonal or double-barrier method of contraception, or sexual abstinence are&#xD;
             the only methods of contraception acceptable for this study)&#xD;
&#xD;
          9. Ongoing infectious disease including human immunodeficiency virus (HIV) and hepatitis&#xD;
&#xD;
         10. Clinically significant respiratory, renal, metabolic, liver, central nervous system or&#xD;
             other comorbid disease, except current cardiovascular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J.J. Finkelstein, BBA</last_name>
    <role>Study Director</role>
    <affiliation>RegeneRx Biopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thymosin Beta 4</keyword>
  <keyword>Thymosin β4 (Tβ4) Injectable Solution</keyword>
  <keyword>RGN-352</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

